Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | USP2 | O75604 | 1/20 | 0.60 |
| ▸ | HTT | P42858 | 1/20 | 0.60 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.60 |
| ▸ | MMP1 | P03956 | 5/20 | 0.48 |
| ▸ | MMP13 | P45452 | 5/20 | 0.48 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.48 |
| ▸ | PLG | P00747 | 3/20 | 0.47 |
| ▸ | PLAU | P00749 | 3/20 | 0.47 |
| ▸ | PLAT | P00750 | 1/20 | 0.46 |
| ▸ | GAA | P10253 | 1/20 | 0.44 |
| ▸ | MCOLN3 | Q8TDD5 | 1/20 | 0.44 |
| ▸ | CA2 | P00918 | 2/20 | 0.44 |
| ▸ | CA1 | P00915 | 1/20 | 0.44 |
| ▸ | MMP2 | P08253 | 1/20 | 0.44 |
| ▸ | MMP9 | P14780 | 1/20 | 0.44 |
| ▸ | MMP8 | P22894 | 1/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.43 |
| ▸ | ADAM17 | P78536 | 2/20 | 0.43 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.43 |
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14676227 | 0.98 | USP2 (0.58) | USP2HTTSMN1; SMN2MMP1MMP13 | |
| SCHEMBL14675849 | 0.95 | USP2 (0.55) | USP2HTTSMN1; SMN2MMP1MMP13 | |
| SCHEMBL7066967 | 0.91 | HTT (0.59) | USP2HTTSMN1; SMN2MMP1MMP13 | |
| SCHEMBL7066448 | 0.87 | MMP13 (0.62) | USP2HTTSMN1; SMN2MMP1MMP13 | |
| SCHEMBL7066058 | 0.86 | USP2 (0.71) | USP2HTTSMN1; SMN2MMP1MMP13 | |
| SCHEMBL7065804 | 0.86 | SMN1; SMN2 (0.60) | USP2HTTSMN1; SMN2MMP1MMP13 | |
| SCHEMBL7067073 | 0.86 | USP2 (0.67) | USP2HTTSMN1; SMN2MMP1MMP13 | |
| SCHEMBL7064268 | 0.86 | HTT (0.60) | USP2HTTSMN1; SMN2MMP1MMP13 | |
| SCHEMBL5674188 | 0.84 | USP2 (0.52) | USP2HTTSMN1; SMN2MMP1MMP13 | |
| SCHEMBL7064055 | 0.84 | USP2 (0.62) | USP2HTTSMN1; SMN2MMP1MMP13 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1616859-B1 | Substituted cyclohexyl carboxylic acid compounds | SEIKAGAKU KOGYO CO LTD (JP) | 2013-09-04 | — | — | EP | claimed |
| EP-1616859-A1 | Substituted cyclohexyl carboxylic acid compounds | SEIKAGAKU CORPORATION (JP) | 2006-01-18 | — | — | EP | claimed |
| EP-1222176-A1 | AMINO LACTAM SULFONAMIDES AS INHIBITORS OF A$g(b) PROTEIN PRODUCTION | Bristol-Myers Squibb Pharma Company (US) | 2002-07-17 | — | — | EP | claimed |
| WO-2001027091-A1 | AMINO LACTAM SULFONAMIDES AS INHIBITORS OF Aβ PROTEIN PRODUCTION | DU PONT PHARMACEUTICALS COMPANY (US) | 2001-04-19 | — | — | WO | claimed |
| EP-1616859-B1 | Substituted cyclohexyl carboxylic acid compounds | SEIKAGAKU KOGYO CO LTD (JP) | 2013-09-04 | — | — | EP | disclosed |
| EP-1616859-B1 | Substituted cyclohexyl carboxylic acid compounds | SEIKAGAKU KOGYO CO LTD (JP) | 2013-09-04 | — | — | EP | disclosed |
| EP-1008592-B1 | Cyclic amide derivatives which inhibit cathepsin K | SEIKAGAKU KOGYO CO LTD (JP) | 2006-02-01 | — | — | EP | disclosed |
| EP-1008592-B1 | Cyclic amide derivatives which inhibit cathepsin K | SEIKAGAKU KOGYO CO LTD (JP) | 2006-02-01 | — | — | EP | disclosed |
| EP-1619189-A1 | N-(3-acyl-2-hydroxyalkyl) cycloalkyl amide derivatives | SEIKAGAKU CORPORATION (JP) | 2006-01-25 | — | — | EP | disclosed |
| EP-1616867-A1 | Hydroxycarboxylic acid derivatives | SEIKAGAKU CORPORATION (JP) | 2006-01-18 | — | — | EP | disclosed |
| EP-1616859-A1 | Substituted cyclohexyl carboxylic acid compounds | SEIKAGAKU CORPORATION (JP) | 2006-01-18 | — | — | EP | disclosed |
| US-20030130251-A1 | Amino lactam sulfonamides as inhibitors of A-beta protein production | THOMPSON LORIN A (US) | 2003-07-10 | — | — | US | disclosed |
| US-6503901-B1 | Alzheimer*s disease and Down*s syndrome treatment | BRISTOL MYERS SQUIBB PHARMA COMPANY | 2003-01-07 | — | — | US | disclosed |
| EP-1222176-A1 | AMINO LACTAM SULFONAMIDES AS INHIBITORS OF A$g(b) PROTEIN PRODUCTION | Bristol-Myers Squibb Pharma Company (US) | 2002-07-17 | — | — | EP | disclosed |
| EP-1218377-A1 | AMINO LACTAM SULFONAMIDES AS INHIBITORS OF A$g(b) PROTEIN PRODUCTION | Bristol-Myers Squibb Pharma Company (US) | 2002-07-03 | — | — | EP | disclosed |
| WO-2001027108-A1 | AMINO LACTAM SULFONAMIDES AS INHIBITORS OF Aβ PROTEIN PRODUCTION | BRISTOL-MYERS SQUIBB PHARMA COMPANY (US) | 2001-04-19 | — | — | WO | disclosed |
| WO-2001027091-A1 | AMINO LACTAM SULFONAMIDES AS INHIBITORS OF Aβ PROTEIN PRODUCTION | DU PONT PHARMACEUTICALS COMPANY (US) | 2001-04-19 | — | — | WO | disclosed |
| US-6117870-A | USEFUL AS THERAPEUTIC DRUG OR PREVENTIVE DRUG OF ARTHRITIS AND RHEUMATISM DUE TO INCREASE OF BONE RESORPTION IN ADDITION TO BONE DISEASES SUCH AS OSTEOPOROSIS, HYPERCALCEMIA, AND PAGET'S DISEASE | FUJIREBIO KABUSHIKI KAISHA (JP) | 2000-09-12 | — | — | US | disclosed |
| EP-1008592-A2 | Cyclic amide derivatives which inhibit cathepsin K | Fujirebio Kabushiki Kaisha (JP) | 2000-06-14 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030130251-A1 | Amino lactam sulfonamides as inhibitors of A-beta protein production | APP, APH1A, BACE1 | USP2 1089/4885HTT 1221/4885SMN1; SMN2 324/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.